OVERBEEK, Kasper A, J POULSEN, M LANZILLOTTA, O VINGE-HOLMQUIST, P MACINGA, A DEMIRCI, D SINDHUNATA, J BACKHUS, H ALGÜL, J BUIJS, P LEVY, M KIRIUKOVA, E GONI, M HOLLENBACH, R MIKSCH, Lumír KUNOVSKÝ, M VUJASINOVIC, S NIKOLIC, L DICKERSON, M HIRTH, M NEURATH, M ZUMBLICK, J VILA, M JALAL, G BEYER, F FROST, S CARRARA, Zdeněk KALA, Petr JABANDŽIEV, G SISMAN, F AKYUZ, G CAPURSO, M FALCONI, A ARLT, F VLEGGAAR, L BARRESI, B GREENHALF, L CZAKÓ, P HEGYI, A HOPPER, M NAYAR, T GRESS, F VITALI, A SCHNEIDER, C HALLORAN, Jan TRNA, A OKHLOBYSTIN, L DAGNA, D CAHEN, D BORDIN, V REBOURS, J MAYERLE, A KAHRAMAN, S RASCH, E CULVER, A KLEGER, E MARTÍNEZ-MONEO, O RØKKE, T HUCL, S OLESEN, M BRUNO, E DELLA-TORRE, U BEUERS, J LÖHR a J ROSENDAHL. Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment. In 54th meeting of the European Pancreatic Club. 2022. ISSN 1424-3903. Dostupné z: https://dx.doi.org/10.1016/j.pan.2022.06.036.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment
Autoři OVERBEEK, Kasper A, J POULSEN, M LANZILLOTTA, O VINGE-HOLMQUIST, P MACINGA, A DEMIRCI, D SINDHUNATA, J BACKHUS, H ALGÜL, J BUIJS, P LEVY, M KIRIUKOVA, E GONI, M HOLLENBACH, R MIKSCH, Lumír KUNOVSKÝ, M VUJASINOVIC, S NIKOLIC, L DICKERSON, M HIRTH, M NEURATH, M ZUMBLICK, J VILA, M JALAL, G BEYER, F FROST, S CARRARA, Zdeněk KALA, Petr JABANDŽIEV, G SISMAN, F AKYUZ, G CAPURSO, M FALCONI, A ARLT, F VLEGGAAR, L BARRESI, B GREENHALF, L CZAKÓ, P HEGYI, A HOPPER, M NAYAR, T GRESS, F VITALI, A SCHNEIDER, C HALLORAN, Jan TRNA, A OKHLOBYSTIN, L DAGNA, D CAHEN, D BORDIN, V REBOURS, J MAYERLE, A KAHRAMAN, S RASCH, E CULVER, A KLEGER, E MARTÍNEZ-MONEO, O RØKKE, T HUCL, S OLESEN, M BRUNO, E DELLA-TORRE, U BEUERS, J LÖHR a J ROSENDAHL.
Vydání 54th meeting of the European Pancreatic Club, 2022.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 30219 Gastroenterology and hepatology
Stát vydavatele Nizozemské království
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.600
Organizační jednotka Lékařská fakulta
ISSN 1424-3903
Doi http://dx.doi.org/10.1016/j.pan.2022.06.036
UT WoS 999
Příznaky Mezinárodní význam
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 22. 11. 2022 10:03.
Anotace
Introduction: Autoimmune pancreatitis (AIP) is a rare disease. Large-scale studies from Europe are lacking, and there is little evidence on the optimum treatment regimen. Purpose: To characterize AIP patients in a large pan-European cohort, study the effectiveness of current treatment regimens, and compare these to non-European cohorts. Materials and methods: We retrospectively analyzed all adults diagnosed since 2005 with AIP type 1 or not-otherwise-specified, who had not undergone pancreatic surgery, in 40 European university hospitals. Results: We screened 1079 individuals with suspected AIP, and included 735 for analysis (69% male; median age 57 years; 85% Caucasian). Rates of complete remission were 61% for those untreated (58/95) and 72% for steroid treatment (454/631). Rates of any remission (complete or partial) were 80% (76/95) for the untreated and 96% (603/631) for steroid-treated patients. Higher steroid doses were not more effective than lower doses (OR 0.428; 95%CI 0.054-3.387) and neither was a starting dose duration longer than two weeks (OR 0.908; 95%CI 0.818-1.009). Elevated IgG4 levels independently decreased the chance of complete remission (OR 0.639; 95%CI 0.427-0.955). Relapse occurred in 30% of patients. Relapses within 6 months of remission induction were independent of the steroid tapering duration, remission induction treatment duration, and total cumulative dose. Conclusions: European AIP patients display a slightly different demography, but the same presentation and course of disease as non-European populations. Their response to steroid treatment seems slightly lower. Patients with an elevated IgG4 level may need closer monitoring during remission induction. For remission induction, a starting dose of 0.4 mg/kg/day with a minimum of 20 mg for 2 weeks is an effective treatment regimen and there is no evidence to support more aggressive regimens.
VytisknoutZobrazeno: 28. 7. 2024 08:26